Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
CC transcript

AVEO PHARMACEUTICALS, INC. (AVEO) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/30/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
01/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/19/2023 4 BATE KENNETH (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 375 shares @ $15, valued at $5.6k
Disposed/sold 1,250 options to buy @ $25.9, valued at $32.4k
Disposed/sold 1,250 options to buy @ $15.7, valued at $19.6k
Disposed/sold 2,515 options to buy @ $16.1, valued at $40.5k
Disposed/sold 2,000 options to buy @ $20, valued at $40k
Disposed/sold 6,402 options to buy @ $9.2, valued at $58.9k
Disposed/sold 7,785 options to buy @ $7, valued at $54.5k
Disposed/sold 4,000 options to buy @ $22.7, valued at $90.8k
Disposed/sold 4,000 options to buy @ $7.6, valued at $30.4k
Disposed/sold 4,000 options to buy @ $7.52, valued at $30.1k
Disposed/sold 12,500 options to buy @ $7.27, valued at $90.9k
01/19/2023 4 EVNIN ANTHONY B (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 41,841 shares @ $15, valued at $627.6k
Disposed/sold 1,250 options to buy @ $25.9, valued at $32.4k
Disposed/sold 1,250 options to buy @ $15.7, valued at $19.6k
Disposed/sold 2,515 options to buy @ $16.1, valued at $40.5k
Disposed/sold 2,000 options to buy @ $20, valued at $40k
Disposed/sold 6,402 options to buy @ $9.2, valued at $58.9k
Disposed/sold 7,785 options to buy @ $7, valued at $54.5k
Disposed/sold 4,000 options to buy @ $22.7, valued at $90.8k
Disposed/sold 4,000 options to buy @ $7.6, valued at $30.4k
Disposed/sold 4,000 options to buy @ $7.52, valued at $30.1k
Disposed/sold 12,500 options to buy @ $7.27, valued at $90.9k
01/19/2023 4 Ledell Jebediah (COO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 170,000 options to buy @ $5.92, valued at $1M
Disposed/sold 27,702 options to buy @ $3.67, valued at $101.7k
01/19/2023 4 Ferraresso Michael (Chief Commercial Officer) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 16,345 shares @ $15, valued at $245.2k
Disposed/sold 20,000 options to buy @ $28.3, valued at $566k
Disposed/sold 3,749 options to buy @ $30.8, valued at $115.5k
Disposed/sold 35,064 options to buy @ $6.2, valued at $217.4k
Disposed/sold 42,499 options to buy @ $5.6, valued at $238k
Disposed/sold 100,000 options to buy @ $9.12, valued at $912k
Disposed/sold 220,000 options to buy @ $3.67, valued at $807.4k
01/19/2023 4 Epperly Corinne (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 10,000 options to buy @ $6.31, valued at $63.1k
Disposed/sold 15,000 options to buy @ $6.46, valued at $96.9k
Disposed/sold 22,500 options to buy @ $4.27, valued at $96.1k
01/19/2023 4 Cullen Kevin Joseph (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 25,000 options to buy @ $6.3, valued at $157.5k
Disposed/sold 22,500 options to buy @ $4.27, valued at $96.1k
01/19/2023 4 Spring Scarlett (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 10,000 options to buy @ $6.6, valued at $66k
Disposed/sold 4,000 options to buy @ $7.52, valued at $30.1k
Disposed/sold 12,500 options to buy @ $7.27, valued at $90.9k
Disposed/sold 22,500 options to buy @ $4.27, valued at $96.1k
01/19/2023 4 Mayes, Gregory T. (Director) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 10,000 options to buy @ $6.1, valued at $61k
Disposed/sold 4,000 options to buy @ $7.52, valued at $30.1k
Disposed/sold 12,500 options to buy @ $7.27, valued at $90.9k
Disposed/sold 22,500 options to buy @ $4.27, valued at $96.1k
01/19/2023 4 BAILEY MICHAEL P (President & CEO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 333,167 shares @ $15, valued at $5M
Disposed/sold 3,249 options to buy @ $77.2, valued at $250.8k
Disposed/sold 11,999 options to buy @ $25.1, valued at $301.2k
Disposed/sold 7,499 options to buy @ $17.7, valued at $132.7k
Disposed/sold 90,000 options to buy @ $8.4, valued at $756k
Disposed/sold 46,000 options to buy @ $10.8, valued at $496.8k
Disposed/sold 75,366 options to buy @ $6, valued at $452.2k
Disposed/sold 99,999 options to buy @ $30.8, valued at $3.1M
Disposed/sold 16,750 options to buy @ $15.7, valued at $263k
Disposed/sold 93,500 options to buy @ $6.2, valued at $579.7k
Disposed/sold 35,302 options to buy @ $5.6, valued at $197.7k
01/19/2023 4 Lucera Erick (CFO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Disposed/sold 50,000 options to buy @ $6.7, valued at $335k
Disposed/sold 100,000 options to buy @ $9.12, valued at $912k
Disposed/sold 218,800 options to buy @ $3.67, valued at $803k
01/19/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
01/19/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
01/19/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
01/19/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
01/19/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/19/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/19/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/19/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/19/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/19/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/19/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/19/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Amended and Restated Certificate of Incorporation of AVEO Pharmaceuticals, Inc",
"Amended and Restated Bylaws of AVEO Pharmaceuticals, Inc",
"LG Chem Completes Acquisition of AVEO Oncology"
01/18/2023 8-K Quarterly results
01/05/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/23/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/22/2022 4 BAILEY MICHAEL P (President & CEO) has filed a Form 4 on AVEO PHARMACEUTICALS, INC.
Txns: Exercised 26,499 options to buy @ $6.2, valued at $164.3k
Exercised 85,722 options to buy @ $5.6, valued at $480k
Exercised 164,525 options to buy @ $3.67, valued at $603.8k
12/20/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/02/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/02/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy